Advanced Tumors Clinical Trial
Official title:
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CS23546 in Subjects With Advanced Tumors
The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.
This study is a single arm, open phase I trial, consisting of a dose escalation phase (single dose+multiple doses) and a dose expansion phase, accompanied by pharmacokinetic and pharmacokinetic studies. The first visit period (21 days) of single dose and multiple doses during the dose-increasing phase is the DLT observation period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06314087 -
iTAPVR Study - Phase II Randomized Study
|
Phase 2 | |
Recruiting |
NCT05390528 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02419417 -
Study of BMS-986158 in Subjects With Select Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT04808453 -
Phase I Study of CPI-300 in Patients With Advanced Tumors
|
Phase 1 | |
Recruiting |
NCT05799183 -
A SHR-1210 BE Study on Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05429008 -
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
|
Phase 1 | |
Terminated |
NCT04198818 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05213767 -
Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04151810 -
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05068856 -
A Study of HRS2543 in Patients With Advanced Tumors
|
Phase 1 | |
Completed |
NCT03781362 -
Study of CPI-100 in Patients With Advanced Tumors
|
Phase 1 | |
Recruiting |
NCT03908814 -
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
|
Phase 1 | |
Recruiting |
NCT05061628 -
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
|
Phase 1 | |
Recruiting |
NCT05867771 -
A Study of PM1022 in Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03444714 -
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
|
Phase 1 |